novo nordisk semaglutide tablet Wegovy Tablets for Weight Management Novo Nordisk wins EU approval

FDA scrutiny of misleading compounded GLP-1 promotion also raises the value of platforms that clearly separate clinical prescribing from product advertising

Retatrutide's triple mechanism may offer slightly better glucose regulation, but the difference is not dramatic based on available data

Gastrointestinal symptoms such as nausea, vomiting, and diarrhea 10 are the most common side effects of GLP-1 RAs and are some of the most common reasons for cessation of the medication

The area at risk was demarcated by the absence of Evans Blue staining

The two systems operate in parallel rather than competing, which is why combining them can produce greater weight loss than either alone

A story about GLP-1 agonists and their use in treating obesity and type II diabetes mellitus